Ulcerative Colitis Drug Development

As a leading CRO company in antibody manufacture, Creative Biolabs has extensive experience in the development of therapeutic antibodies and cell-based therapy for autoimmune diseases such as ulcerative colitis (UC). With unique and outstanding integrated platforms, we can give you the most professional advice from target selection to the pre-clinical candidate.

Introduction to Ulcerative Colitis

UC is a chronic idiopathic inflammatory bowel disease (IBD) of the colon that continuously causes a superficial mucosal inflammation extending from the rectum to the more proximal colon, to varying extents. The hallmark symptoms of UC include bloody diarrhea with rectal urgency and tenesmus.

Axial view computed tomography (CT) scan of a patient with Ulcerative colitis. Fig.1 Axial view computed tomography (CT) scan of a patient with Ulcerative colitis. (Gajendran, 2019)

Treatment of Ulcerative Colitis

A subcutaneously administered fully human anti-tumor necrosis factor (TNF) antibody has been approved by both Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for UC refractory to both steroids and azathioprine. In a study, anti-TNF-naive patients with moderate-to-severe UC unresponsive to conventional treatment were randomly assigned to receive either a placebo or the antibody regimen given 2 weeks apart. At week 6, the antibody regimen induced significantly more clinical response, clinical remission and mucosal healing, and improved quality of life. At week 54, patients treated with antibody achieved significantly more continuous responses, remission, and mucosal healing rates compared with those who received placebo.

Colonoscopy images showing (A) normal colon, (B) mild colitis, (C) moderate colitis, (D) severe colitis. Fig.2 Colonoscopy images showing (A) normal colon, (B) mild colitis, (C) moderate colitis, (D) severe colitis. (Gajendran, 2019)

Our Drug Development Services

The development of new drugs requires not only advanced technology and equipment, but also professional guidance. We have the most advanced instruments and professional scientists to help you develop new drugs. Our scientists will communicate with you so that we can assess the project. Next, we will provide you a specific experimental scheme, and you have the right to know the progress of the project at any time. Finally, a detailed report will be given.

Creative Biolabs provides a range of services to support drug development, including but not limited to:

  • Monoclonal Antibody Development for UC
  • Bispecific Antibody Development for UC
  • Cell-based Therapy for UC

If you want to know more about our services, please ask an expert for a specific consultation on your project.

Reference

  1. Gajendran, M.; et al. A comprehensive review and update on ulcerative colitis. Disease-a-Month. 2019.

For Research Use Only | Not For Clinical Use



Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases

Contact us

USA

  • Location:

  • Call:

  • Fax:

  • Email:

UK

  • Location:

  • Call:

  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2022 Creative Biolabs. All Rights Reserved.